Pharmabiz11h
Enanta Pharma announces top-line results for EDP-323 in phase 2a human challenge study of healthy adults infected with RSV
Watertown, Massachusetts Saturday, September 28, 2024, 18:00 Hrs [IST] ...
Pharmabiz13h
Hyderabad’s healthcare experts welcome UNGA's decision to reduce human deaths from AMR by 10% by 2030
Hyderabad’s healthcare experts welcome UNGA's decision to reduce human deaths from AMR by 10% by 2030: Our Bureau, Mumbai Saturday, September 28, 2024, 15:15 Hrs [IST] Hyderabad ...
Pharmabiz14h
Orion Corporation’s partner Bayer submits sNDA to US FDA for oral androgen receptor inhibitor darolutamide
Orion Corporation’s partner Bayer submits sNDA to US FDA for oral androgen receptor inhibitor darolutamide: Espoo, Finland Saturday, September 28, 2024, 15:00 Hrs [IST] Finnish ...
Pharmabiz14h
CK Birla Hospitals unveils ‘Every Beat Counts’ report: A first-of-its-kind insight into India’s cardiac health crisis
Our Bureau, Mumbai Saturday, September 28, 2024, 14:15 Hrs [IST] ...
Pharmabiz12h
PTC Therapeutics’ PTC518 Huntington's disease programme receives US FDA Fast Track Designation
PTC Therapeutics’ PTC518 Huntington's disease programme receives US FDA Fast Track Designation: Warren, New Jersey Saturday, September 28, 2024, 17:00 Hrs [IST] PTC Therapeutics ...
Pharmabiz15h
Our vision is a cancer-free future generation, where everyone has access to accurate tests and affordable treatment: Meghalaya health minister
Our Bureau, Mumbai Saturday, September 28, 2024, 13:30 Hrs [IST] ...
Pharmabiz19h
Pharming gets UK MHRA marketing authorization for Joenja to treat activated phosphoinositide 3-kinase delta (PI3Kd) syndrome
Pharming gets UK MHRA marketing authorization for Joenja to treat activated phosphoinositide 3-kinase delta (PI3Kd) syndrome: Leiden, the Netherlands Saturday, September 28, 2024, ...
Pharmabiz16h
Omeicos Therapeutics completes enrollment in phase 2a PMD-OPTION study of OMT-28 in primary mitochondrial disease
Omeicos Therapeutics completes enrollment in phase 2a PMD-OPTION study of OMT-28 in primary mitochondrial disease: Berlin, Germany Saturday, September 28, 2024, 13:00 Hrs [IST] Om ...
Pharmabiz14h
BFI partners with CSIR- CDRI to advance biomedical innovation
BFI partners with CSIR- CDRI to advance biomedical innovation: Our Bureau, Mumbai Saturday, September 28, 2024, 14:45 Hrs [IST] CSIR-Central Drug Research Institute (CDRI), a prem ...
Pharmabiz15h
World leaders commit to decisive action on antimicrobial resistance
World leaders commit to decisive action on antimicrobial resistance: Geneva Saturday, September 28, 2024, 14:00 Hrs [IST] Global leaders have approved a political declaration at t ...
Pharmabiz20h
US FDA approves Bristol-Myers Squibb’s antipsychotic drug, Cobenfy for treatment of schizophrenia
US FDA approves Bristol-Myers Squibb’s antipsychotic drug, Cobenfy for treatment of schizophrenia: Maryland Saturday, September 28, 2024, 09:00 Hrs [IST] The US Food and Drug Ad ...
Pharmabiz18h
Enterprise Therapeutics’ novel cystic fibrosis investigational therapy, ETD001 receives rare paediatric disease designation in US
Enterprise Therapeutics’ novel cystic fibrosis investigational therapy, ETD001 receives rare paediatric disease designation in US: Brighton, England Saturday, September 28, 2024 ...